C4 Therapeutics, Inc.

NasdaqGS:CCCC 株式レポート

時価総額：US$318.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

C4 Therapeutics マネジメント

マネジメント 基準チェック /24

C4 Therapeutics'の CEO はAndrew Hirschで、 Sep2020年に任命され、 の在任期間は 3.75年です。 の年間総報酬は$ 3.79Mで、 16.9%給与と83.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.31%を直接所有しており、その価値は$ 872.46K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と6.9年です。

主要情報

Andrew Hirsch

最高経営責任者

US$3.8m

報酬総額

CEO給与比率16.9%
CEO在任期間3.8yrs
CEOの所有権0.3%
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間6.9yrs

経営陣の近況

Recent updates

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14
Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

C4 Therapeutics closes $181M capital raise

Jun 21

C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial

Jun 14

C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy

Jun 07

Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

Jun 02
Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

CEO報酬分析

C4 Therapeutics の収益と比較して、Andrew Hirsch の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

報酬と市場: Andrewの 総報酬 ($USD 3.79M ) は、 US市場 ($USD 1.58M ) の同規模の企業の平均を上回っています。

報酬と収益: Andrewの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Andrew Hirsch (53 yo)

3.8yrs

在職期間

US$3,790,099

報酬

Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Andrew Hirsch
CEO, President & Director3.8yrsUS$3.79m0.31%
$ 975.7k
Kenneth Anderson
Co-Founderno dataUS$111.41k0.46%
$ 1.5m
Stewart Fisher
Chief Scientific Officer6.1yrsUS$1.53m0.34%
$ 1.1m
Leonard M. Reyno
Chief Medical Officerless than a yearUS$1.96m0.14%
$ 453.7k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Kendra Adams
CFO & Treasurerless than a yearデータなし0.013%
$ 42.1k
Mark Mossler
Chief Accounting Officerless than a yearデータなし0.0022%
$ 6.9k
Jolie Siegel
Chief Legal Officer & Corporate Secretary3.9yrsUS$3.38m0.014%
$ 46.1k
Kelly Schick
Chief People Officer3.4yrsデータなし0.014%
$ 46.1k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development8.3yrsデータなしデータなし
Christopher Nasveschuk
Senior Vice President of Chemistry3.4yrsデータなしデータなし
Roy Pollock
Senior Vice President of Biological Sciences5.3yrsデータなしデータなし

3.6yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: CCCCの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Andrew Hirsch
CEO, President & Director3.7yrsUS$3.79m0.31%
$ 975.7k
Kenneth Anderson
Co-Founder8.5yrsUS$111.41k0.46%
$ 1.5m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board7.6yrsデータなしデータなし
Bruce Downey
Lead Independent Director8.5yrsUS$157.91k0.71%
$ 2.3m
Malcolm Salter
Independent Director8.5yrsUS$121.91k0.038%
$ 120.4k
Christopher Bowden
Member of Clinical Advisory Boardno dataデータなしデータなし
Christopher Kirk
Member of Scientific Advisory Board7.6yrsデータなしデータなし
Ross Levine
Member of Scientific Advisory Board6.9yrsデータなしデータなし
Ronald H. Cooper
Independent Chairmanno dataデータなしデータなし
Ryan Corcoran
Member of Scientific Advisory Board4.8yrsデータなしデータなし
Scott Armstrong
Member of Scientific Advisory Board6.9yrsデータなしデータなし
Utpal Koppikar
Independent Director2.3yrsUS$126.41k0.0082%
$ 26.3k

6.9yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: CCCCの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。